LY 3202328

Drug Profile

LY 3202328

Alternative Names: LY3202328

Latest Information Update: 21 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class Antihyperlipidaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Dyslipidaemias

Most Recent Events

  • 01 Feb 2017 Eli Lilly completes a phase I trial for Dyslipidaemias in USA (PO) (NCT02714569)
  • 16 Mar 2016 Preclinical trials in Dyslipidaemias in USA (PO) before March 2016
  • 01 Mar 2016 Phase-I clinical trials in Dyslipidaemias in USA (PO) (NCT02714569)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top